Trial Profile
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2021
Price :
$35
*
At a glance
- Drugs Suvecaltamide (Primary)
- Indications Essential tremor
- Focus Proof of concept; Therapeutic Use
- Acronyms T-CALM Sudy
- Sponsors Cavion; Jazz Pharmaceuticals plc
- 25 Mar 2021 Results published in the Movement Disorders
- 16 Sep 2020 Results of subgroup analysis by baseline tremor severity assessig safety and efficacay of CX-8998, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 May 2020 Results (N=83), subgroup analysis by baseline tremor severity, presented at the 72nd Annual Meeting of the American Academy of Neurology